{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=66", "query": { "intervention": "Part 3", "page": 66 }, "page_size": 10 }, "pagination": { "page": 66, "page_size": 10, "total_count": 4019, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=67&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=65&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T11:28:22.561Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04072952", "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vepdegestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Estrogen Receptor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2019-09-22", "completion_date": "2026-03-05", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 16, "location_summary": "Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072952" }, { "nct_id": "NCT06016738", "title": "OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Advanced Breast Cancer", "Metastatic Breast Cancer", "ER Positive Breast Cancer", "HER2 Negative Breast Carcinoma" ], "interventions": [ { "name": "Palazestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2023-11-16", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 47, "location_summary": "Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016738" }, { "nct_id": "NCT03211247", "title": "Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peanut Allergy" ], "interventions": [ { "name": "Part A Viaskin Peanut 250 mcg", "type": "BIOLOGICAL" }, { "name": "Part A Viaskin Peanut 100 mcg", "type": "BIOLOGICAL" }, { "name": "Part A Placebo", "type": "BIOLOGICAL" }, { "name": "Part B Viaskin Peanut 250 mcg", "type": "BIOLOGICAL" }, { "name": "Part B Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "DBV Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "3 Years", "sex": "ALL", "summary": "1 Year to 3 Years" }, "enrollment_count": 414, "start_date": "2017-07-31", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 27, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03211247" }, { "nct_id": "NCT00962091", "title": "Study of MLN8237 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2009-09-25", "completion_date": "2014-07-01", "has_results": true, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00962091" }, { "nct_id": "NCT03321526", "title": "A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "JNJ-42847922", "type": "DRUG" }, { "name": "Placebo Matching to JNJ-42847922", "type": "DRUG" }, { "name": "Quetiapine XR", "type": "DRUG" }, { "name": "Placebo Matching to Quetiapine XR", "type": "DRUG" }, { "name": "Selective Serotonin Reuptake Inhibitor (SSRI)", "type": "DRUG" }, { "name": "Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 107, "start_date": "2017-12-12", "completion_date": "2019-06-27", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321526" }, { "nct_id": "NCT04021368", "title": "RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "High-risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "RVU120(SEL120)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ryvu Therapeutics SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2019-09-04", "completion_date": "2024-05-21", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 5, "location_summary": "Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04021368" }, { "nct_id": "NCT01521143", "title": "Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "Cvac", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Prima BioMed Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 91, "start_date": "2012-01", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 6, "location_summary": "Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01521143" }, { "nct_id": "NCT06396897", "title": "Hospital @ Home Model of Care for Cirrhosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Decompensated Cirrhosis" ], "interventions": [ { "name": "Indiana University Health Hospital at Home Program", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-05-10", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06396897" }, { "nct_id": "NCT01859858", "title": "Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Cancer" ], "interventions": [ { "name": "curcumin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "21 Years to 99 Years" }, "enrollment_count": 23, "start_date": "2013-06", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2023-12-04", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Chapel Hill, North Carolina", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859858" }, { "nct_id": "NCT03720678", "title": "A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "GastroEsophageal Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "etrumadenant", "type": "DRUG" }, { "name": "mFOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-11-18", "completion_date": "2021-06-25", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-11-12T11:28:22.561Z", "location_count": 17, "location_summary": "Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03720678" } ] }